clinical trial · NCT06963398
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 520
Advanced Solid TumorsHS-10529
brief summary
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
started
May 15, 2025
primary completion
Apr 30, 2029
completion
Aug 30, 2029
last updated
May 9, 2025
detailed description
This is a phase 1, first-in-human, study of HS-10529, consisting of dose escalation and dose expansion, which is aimed to assess the safety and tolerability of HS-10529 in KRAS G12D patients with advanced solid tumors and evaluate the preliminary efficacy of HS-10529.
official title
A Phase 1 Study, Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10529 Monotherapy in KRAS G12D Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol